Phase Angle and Dry Weight Benefit Nutritional Management of a Patient with Primary Myelofibrosis Undergoing Allogeneic Hematopoietic Stem Cell Transplantation
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
Online-Ressource
- Language
-
Englisch
- Bibliographic citation
-
Phase Angle and Dry Weight Benefit Nutritional Management of a Patient with Primary Myelofibrosis Undergoing Allogeneic Hematopoietic Stem Cell Transplantation ; volume:2 ; number:1-3 ; year:2019 ; pages:16-20
Case reports in clinical nutrition ; 2, Heft 1-3 (2019), 16-20
- Creator
-
Novelli, Isabelle
Fatobene, Giancarlo
Silva, Ana Carolina
Rodrigues, Ana Lucia
Severine, Ariane
Rocha, Vanderson
Hirose, Erika Yuri
- DOI
-
10.1159/000498982
- URN
-
urn:nbn:de:101:1-2020100101280327898780
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:47 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Novelli, Isabelle
- Fatobene, Giancarlo
- Silva, Ana Carolina
- Rodrigues, Ana Lucia
- Severine, Ariane
- Rocha, Vanderson
- Hirose, Erika Yuri
Other Objects (12)
Long-term outcome after allogeneic hematopoietic cell transplantation for myelofibrosis
Long-term outcome after allogeneic hematopoietic cell transplantation for myelofibrosis
Impact of myelofibrosis on patients with myelodysplastic syndromes following allogeneic hematopoietic stem cell transplantation
Allogeneic hematopoietic cell transplantation for myelofibrosis in patients pretreated with the JAK1 and JAK2 inhibitor ruxolitinib
Allogeneic hematopoietic cell transplantation in older myelofibrosis patients: a study of the chronic malignancies working party of EBMT and the Spanish Myelofibrosis Registry
Allogeneic hematopoietic cell transplantation in older myelofibrosis patients: A study of the chronic malignancies working party of EBMT and the Spanish Myelofibrosis Registry
Allogeneic hematopoietic cell transplantation in older myelofibrosis patients: A study of the chronic malignancies working party of EBMT and the Spanish Myelofibrosis Registry
Importance of allogeneic stem cell transplantation in myelofibrosis
Splenic irradiation before allogeneic stem cell transplantation for myelofibrosis
Nutritional status and quality of life in adults undergoing allogeneic hematopoietic stem cell transplantation
Allogeneic hematopoietic cell transplantation for myelofibrosis aged 70 years or older: a study from the German Registry for Stem Cell Transplantation
Myelofibrosis
Long-term outcome after allogeneic hematopoietic cell transplantation for myelofibrosis
Long-term outcome after allogeneic hematopoietic cell transplantation for myelofibrosis
Impact of myelofibrosis on patients with myelodysplastic syndromes following allogeneic hematopoietic stem cell transplantation
Allogeneic hematopoietic cell transplantation for myelofibrosis in patients pretreated with the JAK1 and JAK2 inhibitor ruxolitinib
Allogeneic hematopoietic cell transplantation in older myelofibrosis patients: a study of the chronic malignancies working party of EBMT and the Spanish Myelofibrosis Registry
Allogeneic hematopoietic cell transplantation in older myelofibrosis patients: A study of the chronic malignancies working party of EBMT and the Spanish Myelofibrosis Registry
Allogeneic hematopoietic cell transplantation in older myelofibrosis patients: A study of the chronic malignancies working party of EBMT and the Spanish Myelofibrosis Registry
Importance of allogeneic stem cell transplantation in myelofibrosis
Splenic irradiation before allogeneic stem cell transplantation for myelofibrosis
Nutritional status and quality of life in adults undergoing allogeneic hematopoietic stem cell transplantation
Allogeneic hematopoietic cell transplantation for myelofibrosis aged 70 years or older: a study from the German Registry for Stem Cell Transplantation
Myelofibrosis
Long-term outcome after allogeneic hematopoietic cell transplantation for myelofibrosis
Long-term outcome after allogeneic hematopoietic cell transplantation for myelofibrosis
Impact of myelofibrosis on patients with myelodysplastic syndromes following allogeneic hematopoietic stem cell transplantation
Allogeneic hematopoietic cell transplantation for myelofibrosis in patients pretreated with the JAK1 and JAK2 inhibitor ruxolitinib
Allogeneic hematopoietic cell transplantation in older myelofibrosis patients: a study of the chronic malignancies working party of EBMT and the Spanish Myelofibrosis Registry
Allogeneic hematopoietic cell transplantation in older myelofibrosis patients: A study of the chronic malignancies working party of EBMT and the Spanish Myelofibrosis Registry
Allogeneic hematopoietic cell transplantation in older myelofibrosis patients: A study of the chronic malignancies working party of EBMT and the Spanish Myelofibrosis Registry
Importance of allogeneic stem cell transplantation in myelofibrosis
Splenic irradiation before allogeneic stem cell transplantation for myelofibrosis
Nutritional status and quality of life in adults undergoing allogeneic hematopoietic stem cell transplantation
Allogeneic hematopoietic cell transplantation for myelofibrosis aged 70 years or older: a study from the German Registry for Stem Cell Transplantation